Aik Na Tan - 11 Aug 2026 Form 4 Insider Report for Wave Life Sciences, Inc. (WVE)

Reporting relationship: Director
Issuer ticker: WVE
Reported as of: 11 Aug 2026
Net transaction value: -$2,596
SEC form: 4
Accepted by SEC: 13 Aug 2026, 21:00:05 UTC
Prior SEC filing: 10 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Aik Na Tan

Key filing fact

Aik Na Tan filed Form 4 for Wave Life Sciences, Inc. (WVE) on 13 Aug 2026.

Key facts

This page summarizes Aik Na Tan's Form 4 filing for Wave Life Sciences, Inc. (WVE).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 13 Aug 2026, 21:00.

Change

Previous filing in this sequence was filed on 10 Dec 2025.
Current net transaction value: -$2,596.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001821285 Primary reporting owner

Tan Aik Na

Relationship: Director
Address: C/O WAVE LIFE SCIENCES, INC.,, 733 CONCORD AVE., CAMBRIDGE
Signature: /s/ Aik Na Tan
Signature date: 13 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

WVE transaction

Common Stock

Sale

Transaction value: $2,596
Shares: -432
Change %: -1.7%
Price: $6.01
Shares after: 24,968
Date: 11 Aug 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 1 footnote

Footnote F1

On August 11, 2026, the reporting person sold 432 shares of common stock solely to cover taxes associated with the vesting of restricted stock units on August 11, 2026. These sales were made pursuant to a previously adopted 10b5-1 Trading Plan.

SEC remarks

On August 7, 2026, Wave Life Sciences, Inc., a Delaware corporation, became the successor of Wave Life Sciences Ltd., a company organized under the laws of the Republic of Singapore ("Wave-Singapore"), pursuant to a scheme of arrangement under Singapore law under which all issued ordinary shares in the capital of Wave-Singapore were exchanged on a one-for-one basis for shares of common stock of Wave Life Sciences, Inc. (the "Redomiciliation"). The Redomiciliation had the effect of changing Wave-Singapore's domicile, but did not alter the proportionate interests of securityholders. Exhibit 24.1 - Power of Attorney